Plant Advanced Technologies PAT SA banner

Plant Advanced Technologies PAT SA
PAR:ALPAT

Watchlist Manager
Plant Advanced Technologies PAT SA Logo
Plant Advanced Technologies PAT SA
PAR:ALPAT
Watchlist
Price: 6.6 EUR -0.9% Market Closed
Market Cap: €7.5m

Relative Value

The Relative Value of one ALPAT stock under the Base Case scenario is hidden EUR. Compared to the current market price of 6.6 EUR, Plant Advanced Technologies PAT SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALPAT Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

ALPAT Competitors Multiples
Plant Advanced Technologies PAT SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Plant Advanced Technologies PAT SA
PAR:ALPAT
7.4m EUR 7.8 23.1 25.2 -34.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
364.6B USD 6 87.1 14.5 20.1
US
Amgen Inc
NASDAQ:AMGN
188.6B USD 5.1 24.4 14.2 14.2
US
Gilead Sciences Inc
NASDAQ:GILD
175.1B USD 6 20.6 12.9 15.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.3B USD 9.7 29.4 22.2 23.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.9B USD 5.4 17.3 12.7 14.5
AU
CSL Ltd
ASX:CSL
66.6B AUD 3.1 33.8 11.2 14.1
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
NL
argenx SE
XBRU:ARGX
36.4B EUR 10.3 33.1 35.8 36.5
P/S Multiple
Revenue Growth P/S to Growth
FR
Plant Advanced Technologies PAT SA
PAR:ALPAT
Average P/S: 3 063 003.4
7.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
6
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.7
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
10%
0.5
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
NL
argenx SE
XBRU:ARGX
10.3
27%
0.4
P/E Multiple
Earnings Growth PEG
FR
Plant Advanced Technologies PAT SA
PAR:ALPAT
Average P/E: 33.6
23.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.1
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.4
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.6
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.4
16%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
13%
1.3
AU
CSL Ltd
ASX:CSL
33.8
10%
3.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
NL
argenx SE
XBRU:ARGX
33.1
32%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Plant Advanced Technologies PAT SA
PAR:ALPAT
Average EV/EBITDA: 18.6
25.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.5
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
18%
0.7
AU
CSL Ltd
ASX:CSL
11.2
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
NL
argenx SE
XBRU:ARGX
35.8
50%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Plant Advanced Technologies PAT SA
PAR:ALPAT
Average EV/EBIT: 19.8
Negative Multiple: -34.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.1
24%
0.8
US
Amgen Inc
NASDAQ:AMGN
14.2
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.9
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.5
23%
0.6
AU
CSL Ltd
ASX:CSL
14.1
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
NL
argenx SE
XBRU:ARGX
36.5
56%
0.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett